Related Experiment Video
Updated: Oct 7, 2025
07:54
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
7.0K
[Progress in treatment for malignant pleural mesothelioma]
1Department of Thoracic Medical Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Beijing Institute for Cancer Research, Beijing 100142, China.
Summary
Malignant pleural mesothelioma (MPM) treatment faces challenges due to poor prognosis and limited second-line options. This review explores current research and future directions for improving MPM therapy, including immune checkpoint inhibitors.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer with poor prognosis.
- Current first-line treatment involves chemotherapy (pemetrexed/platinum) ± bevacizumab, but resistance limits options.
- There is no standard second-line therapy for MPM, with limited efficacy from existing regimens.
Purpose of the Study:
- To review the latest clinical studies and research in malignant pleural mesothelioma treatment.
- To explore the potential and future directions for improving therapeutic efficacy in MPM.
- To summarize the role of immune checkpoint inhibitors (ICIs) in MPM treatment.
Main Methods:
- Literature review of recent clinical studies and research on MPM treatment.
- Analysis of the efficacy and limitations of current and emerging therapies.
- Examination of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors in MPM.
Main Results:
- First-line chemotherapy offers limited survival benefits, and resistance develops quickly.
- Second-line treatments like monotherapy have a median progression-free survival (PFS) of only 3 months.
- Immune checkpoint inhibitors (ICIs) show promise but have limited overall efficacy improvement in MPM.
Conclusions:
- Improving therapeutic strategies for malignant pleural mesothelioma is critical due to poor outcomes.
- Further research into novel agents and combination therapies, including ICIs, is needed.
- Future directions may involve optimizing ICI therapy and exploring new treatment paradigms for MPM.
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
347
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
347
01:28Pleural Effusion II: Symptoms and Management
315
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
315
01:27Pneumothorax-II
437
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
437
02:07Tumor Progression
6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:27Pulmonary Embolism III: Nursing Management
67
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
67